Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia

Haematologica

Volumn 99, Issue 5, 2014, Pages 881-887

  Perbellini, Omar ^a   Falisi, Erika ^b   Giaretta, Ilaria ^b   Boscaro, Elisa ^c   Novella, Elisabetta ^b   Facco, Monica ^c   Fortuna, Stefania ^d   Finotto, Silvia ^b   Amati, Eliana ^a   Maniscalco, Francesco ^a   Montaldi, Anna ^b   Alghisi, Alberta ^b   Aprili, Fiorenza ^e   Bonaldi, Laura ^f   Paolini, Rossella ^g   Scupoli, Maria Teresa ^a   Trentin, Livio ^c   Ambrosetti, Achille ^a   Semenzato, Gianpietro ^c   Pizzolo, Giovanni ^a   Rodeghiero, Francesco ^b   Visco, Carlo ^b   more..

^a UNIVERSITY OF VERONA   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d Department of Medicine Azienda ULSS N4 Alto Vicentino   (Italy)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^g SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; CD38 ANTIGEN; LEUKOCYTE ASSOCIATED IMMUNOGLOBULIN LIKE RECEPTOR 1; RECEPTOR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE-ASSOCIATED IMMUNOGLOBULIN-LIKE RECEPTOR 1;

ADULT; AGED; ARTICLE; B LYMPHOCYTE ACTIVATION; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL PREDICTION; TIME TO TREATMENT; CANCER STAGING; CHROMOSOME ABERRATION; DISEASE COURSE; GENE EXPRESSION; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC;

EID: 84899716283     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.096362     Document Type: Article

References (27)

1. Rosenquist R, Cortese D, Bhoi S, Mansouri L, Gunnarsson R. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? Leuk Lymphoma. 2013; 54(11): 2351-64.
2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46(2): 219-34.
3. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981; 48(1): 198-206.
4. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6): 1840-7.
5. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V-H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94(6): 1848-54.
6. Hamblin TJ, Orchard JA, Gardiner A, Oscier DG, Davis Z, Stevenson FK. Immuno-globulin V genes and CD38 expression in CLL. Blood. 2000; 95(7): 2455-7.
7. Chiorazzi N. Implications of new prognostic markers in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2012: 76-87.
8. Gattei V, Bulian P, Del Principe MI, Zucchetto A, Maurillo L, Buccisano F, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood. 2008; 111(2): 865-73.
9. Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS, et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol. 2008; 140(5): 537-46.
10. Rossi D, Zucchetto A, Rossi FM, Capello D, Cerri M, Deambrogi C, et al. CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. Haematologica. 2008; 93(10): 1575-9.
11. Huang PY, Best OG, Belov L, Mulligan SP, Christopherson RI. Surface profiles for subclassification of chronic lymphocytic leukemia. Leuk Lymphoma. 2012; 53(6): 1046-56.
12. Del Poeta G, Del Principe MI, Zucchetto A, Luciano F, Buccisano F, Rossi FM, et al. CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. Haematologica. 2012; 97(2): 279-87.
13. Meyaard L. The inhibitory collagen receptor LAIR1 (CD305). J Leukoc Biol. 2008; 83 (4): 799-803.
14. Son M, Santiago-Schwarz F, Al-Abed Y, Diamond B. C1q limits dendritic cell differentiation and activation by engaging LAIR1. Proc Natl Acad Sci USA. 2012; 109 (46): E3160-E7.
15. van der Vuurst de Vries AR, Clevers H, Logtenberg T, Meyaard L. Leukocyte-associated immunoglobulin-like receptor-1 (LAIR1) is differentially expressed during human B cell differentiation and inhibits B cell receptor-mediated signaling. Eur J Immunol. 1999; 29(10): 3160-7.
16. Poggi A, Catellani S, Bruzzone A, Caligaris-Cappio F, Gobbi M, Zocchi MR. Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division. Leukemia. 2008; 22(5): 980-8.
17. Rawstron AC, Shingles J, de Tute R, Bennett F, Jack AS, Hillmen P. Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing. Cytometry B Clin Cytom. 2010; 78B: S42-S6.
18. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Doehner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111 (12): 5446-56.
19. Clinical and Laboratory Standards Institute. Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline-Second Edition. CLSI document H43-A2 [ISBN 1-56238-635-2]. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2007.
20. Visco C, Moretta F, Falisi E, Facco M, Maura F, Novella E, et al. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. Am J Hematol. 2013; 88(4): 277-82.
21. Falisi E, Novella E, Visco C, Guercini N, Maura F, Giaretta I, et al. B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities. Hematol Oncol. 2014; 32(1): 22-30.
22. Zucchetto A, Bomben R, Dal Bo M, Bulian P, Benedetti D, Nanni P, et al. CD49d in Bcell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance. Leukemia. 2006; 20(3): 523-5.
23. Perbellini O, Zampieri F, Vincenzi C, Perantoni P, Mosna F, Boscaro E, et al. Regione Veneto study group on B-CLL: standardization of ZAP-70 evaluation by flow cytometry. Haematologica. 2008; 93 (s2): S97.
24. Visco C, Novella E, Peotta E, Paolini R, Giaretta I, Rodeghiero F. Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. Haematologica. 2010; 95(7): 1230-2.
25. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1): 32-42.
26. Colombo BM, Canevali P, Magnani O, Rossi E, Puppo F, Zocchi MR, et al. Defective expression and function of the leukocyte associated Ig-like receptor 1 in B lymphocytes from systemic lupus erythematosus patients. PLoS One. 2012; 7(2): e31903.
27. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood. 2012; 120(24): 4684-91.